Target and Technology
Tisotumab vedotin is an antibody-drug conjugate (ADC) composed of a human antibody targeted to tissue factor (TF) and our ADC technology that utilizes a protease-cleavable linker and the potent microtubule-disrupting agent monomethyl auristatin E (MMAE). TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial and lung. We are co-developing tisotumab vedotin with Genmab.
Our ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.
Clinical Development Status
- A potentially registrational phase 2 trial in recurrent and/or metastatic cervical cancer is planned
- Two additional phase 2 trials, in frontline cervical cancer and in other solid tumors, are planned
Phase 1/2 clinical studies for solid tumors are ongoing